# A Study of ANV419 Alone or in Combination With Approved Treatment in Patients With Cutaneous Melanoma (OMNIA-1).

> **NCT05578872** · PHASE1,PHASE2 · COMPLETED · sponsor: **Anaveon AG** · enrollment: 29 (actual)

## Conditions studied

- Melanoma (Skin)
- Cutaneous Melanoma
- Adult Disease
- Advanced Solid Tumor
- Metastatic Melanoma

## Interventions

- **DRUG:** ANV419

## Key facts

- **NCT ID:** NCT05578872
- **Lead sponsor:** Anaveon AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-12-16
- **Primary completion:** 2024-08-01
- **Final completion:** 2024-08-01
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2025-08-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05578872

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05578872, "A Study of ANV419 Alone or in Combination With Approved Treatment in Patients With Cutaneous Melanoma (OMNIA-1).". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05578872. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*